Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this post-marketing surveillance is to obtain further information about the tolerability of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Fenoterol; Fenoterol, ipratropium drug combination; Ipratropium

Criteria

Inclusion Criteria:

• Patients with diagnosis of Chronic obstructive respiratory tract disease

• Patients of either sex, including children over 6 years

Exclusion Criteria:

• Contraindications listed in the Instructions of Use/Summary of Product Characteristics of Berodual® metered-dose inhaler